Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

PHASE2UnknownINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

February 23, 2024

Study Completion Date

February 23, 2024

Conditions
Ovarian Cancer
Interventions
DRUG

Paclitaxel (albumin-bound)

The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.

Trial Locations (1)

100021

National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Chinese Academy of Medical Sciences

OTHER

NCT04661696 - Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. | Biotech Hunter | Biotech Hunter